AU728610B2 - Chimeric retrovirus/adenovirus system - Google Patents

Chimeric retrovirus/adenovirus system Download PDF

Info

Publication number
AU728610B2
AU728610B2 AU54475/98A AU5447598A AU728610B2 AU 728610 B2 AU728610 B2 AU 728610B2 AU 54475/98 A AU54475/98 A AU 54475/98A AU 5447598 A AU5447598 A AU 5447598A AU 728610 B2 AU728610 B2 AU 728610B2
Authority
AU
Australia
Prior art keywords
retroviral
vector
adenoviral
cells
functions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU54475/98A
Other languages
English (en)
Other versions
AU5447598A (en
Inventor
David T Curiel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UAB Research Foundation
Original Assignee
UAB Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by UAB Research Foundation filed Critical UAB Research Foundation
Publication of AU5447598A publication Critical patent/AU5447598A/en
Application granted granted Critical
Publication of AU728610B2 publication Critical patent/AU728610B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10344—Chimeric viral vector comprising heterologous viral elements for production of another viral vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
    • C12N2810/6072—Vectors comprising as targeting moiety peptide derived from defined protein from viruses negative strand RNA viruses
    • C12N2810/6081—Vectors comprising as targeting moiety peptide derived from defined protein from viruses negative strand RNA viruses rhabdoviridae, e.g. VSV

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
AU54475/98A 1996-11-19 1997-11-19 Chimeric retrovirus/adenovirus system Ceased AU728610B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US3132396P 1996-11-19 1996-11-19
US60/031323 1996-11-19
US3708197P 1997-02-04 1997-02-04
US60/037081 1997-02-04
PCT/US1997/021169 WO1998022143A1 (en) 1996-11-19 1997-11-19 Chimeric retrovirus/adenovirus system

Publications (2)

Publication Number Publication Date
AU5447598A AU5447598A (en) 1998-06-10
AU728610B2 true AU728610B2 (en) 2001-01-11

Family

ID=26707084

Family Applications (1)

Application Number Title Priority Date Filing Date
AU54475/98A Ceased AU728610B2 (en) 1996-11-19 1997-11-19 Chimeric retrovirus/adenovirus system

Country Status (8)

Country Link
US (1) US6333030B1 (enExample)
EP (1) EP0956052B1 (enExample)
JP (1) JP4214239B2 (enExample)
AT (1) ATE292983T1 (enExample)
AU (1) AU728610B2 (enExample)
CA (1) CA2272121A1 (enExample)
DE (1) DE69733035T2 (enExample)
WO (1) WO1998022143A1 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010006629A1 (en) * 1993-10-25 2001-07-05 Richard J. Gregory Recombinant adenoviral vector and methods of use
AU687117B2 (en) * 1993-10-25 1998-02-19 Canji, Inc. Recombinant adenoviral vector and methods of use
US6210939B1 (en) 1993-10-25 2001-04-03 Canji, Inc. Recombinant adenoviral vector and methods of use
US20060275261A1 (en) * 1993-10-25 2006-12-07 Canji, Inc. Adenoviral vectors having a protein IX deletion
JP2001518804A (ja) * 1997-03-21 2001-10-16 エンゾー セラピューティクス インコーポレイテッド ベクターおよびウイルスベクター、およびこれらを増殖するためのパッケージング細胞株
US8703480B1 (en) 1997-03-21 2014-04-22 Enzo Therapeutics, Inc. Biological function effecting viral vectors and chimeric cells useful as packaging cell lines and target cells
AU6962698A (en) 1997-04-11 1998-11-11 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Transgenomic viruses and the use thereof
WO1999044423A1 (en) * 1998-03-03 1999-09-10 The Uab Research Foundation Amplification of gene transfer and gene therapy by controlled replication
US20060183228A1 (en) * 1998-03-24 2006-08-17 Enzo Therapeutics, Inc. Viral vectors with surface or envelope components
FR2778670B1 (fr) 1998-05-18 2002-12-13 Rhone Poulenc Rorer Sa Methodes et compositions pour la production de particules virales
AU6149099A (en) * 1998-09-22 2000-04-10 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Replication deficient retroviral vector system and methods of using
US7052904B2 (en) 2000-01-31 2006-05-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Hybrid adeno-retroviral vector for the transfection of cells
EP1287153B1 (en) 2000-05-31 2009-09-30 Human Gene Therapy Research Institute Methods and compositions for efficient gene transfer using transcomplementary vectors
US7226779B2 (en) 2001-01-30 2007-06-05 The United States Of America As Represented By The Department Of Health And Human Services Hybrid adenoviral vector
US7271150B2 (en) 2001-05-14 2007-09-18 United States Of America, Represented By The Secretary, Department Of Health And Human Services Modified growth hormone
EP1442125A4 (en) * 2001-10-04 2004-12-08 Carlos Estuard Aguilar-Cordova CHIMERAL VIRUS VECTORS FOR GENE THERAPY
US20070037284A1 (en) * 2003-06-04 2007-02-15 Enzo Therapeutics, Inc. Vectors for expressing exogenous gene or exogenous nucleic acid sequences
ES2292271B1 (es) * 2004-05-20 2009-02-16 Proyecto De Biomedicina Cima, S.L. Un vector hibrido adenovirus-alfavirus para la administracion eficaz y expresion de genes terapeuticos en celulas tumorales.
WO2011123518A1 (en) 2010-03-31 2011-10-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Adenosine receptor agonists for the treatment and prevention of vascular or joint capsule calcification disorders
WO2021108500A1 (en) 2019-11-26 2021-06-03 University Of Pittsburgh - Of The Commonwealth System Of Higher Education T cell receptors targeting mutations in rna splicing factors
US20230348557A1 (en) 2020-02-06 2023-11-02 University Of Pittsburgh - Of The Commonwealth System Of Higher Education T cell receptors Targeting Defective DNA Repair Proteins
US10822379B1 (en) 2020-03-12 2020-11-03 University of Pittsburgh—of the Commonwealth System of Higher Education Molecules that bind to SARS-CoV-2

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997025446A1 (en) * 1996-01-05 1997-07-17 Genetic Therapy, Inc. Recombinase-mediated generation of adenoviral vectors

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BILBAO G ET AL. J. FASEB, 1997, 11(8):624-634 *
SMITH AE ET AL. ANN. REVIEW OF MICROBIOLOGY, 1995,49:807-838 *

Also Published As

Publication number Publication date
EP0956052A1 (en) 1999-11-17
AU5447598A (en) 1998-06-10
US6333030B1 (en) 2001-12-25
JP2001509009A (ja) 2001-07-10
JP4214239B2 (ja) 2009-01-28
WO1998022143A1 (en) 1998-05-28
EP0956052B1 (en) 2005-04-13
ATE292983T1 (de) 2005-04-15
CA2272121A1 (en) 1998-05-28
DE69733035T2 (de) 2005-11-24
DE69733035D1 (en) 2005-05-19
EP0956052A4 (en) 2001-05-02

Similar Documents

Publication Publication Date Title
AU728610B2 (en) Chimeric retrovirus/adenovirus system
Feng et al. Stable in vivo gene transduction via a novel adenoviral/retroviral chimeric vector
Logg et al. A uniquely stable replication-competent retrovirus vector achieves efficient gene delivery in vitro and in solid tumors
US5925345A (en) Vectors including foreign genes and negative selective markers
US6156497A (en) Recombinase-mediated generation of adenoviral vectors
Tai et al. Replication-competent retrovirus vectors for cancer gene therapy
JP2001517452A (ja) 機能的スプライス・ドナー部位及び機能的スプライス・アクセプター部位を含むレトロウイルスベクター
CN103314107B (zh) 具有重组的基因表达调控序列的肿瘤特异性表达得到改善的基因运载体
EP1059357A1 (en) Replicating or semi-replicating retroviral constructs, preparation and uses for gene delivery
Duisit et al. Functional characterization of adenoviral/retroviral chimeric vectors and their use for efficient screening of retroviral producer cell lines
CN105579581A (zh) 具有优化的a凸出物的重组载体
EP0723460A1 (en) Gene therapy of the nervous system
US20100233125A1 (en) Chimeric adenovirus, method for producing the same and pharmaceutical using the same
US5710037A (en) Retroviral vector particles
WO1995034639A9 (en) Novel retroviral envelope and ltr and retroviral vector particles including such envelope and/or ltr
CA2237000A1 (en) Stable packaging cell line producing pseudotyped retroviruses
JP2007530004A (ja) 疾患を処置するためのサブグループｂアデノウイルスベクター
Ponder Vectors in gene therapy
US6303380B1 (en) Construction of retroviral producer cells from adenoviral and retroviral vectors
SK56198A3 (en) Use of protein gax for treating cancer
JPH11266885A (ja) ベクタ―成分の配列を含有するキメラポックスウイルス
US6762031B2 (en) Targeting viral vectors to specific cells
JP2002539797A (ja) 機能的および非機能的なスプライス供与部位ならびにスプライス受容部位を含むレトロウイルスベクター
EP0977881B1 (en) Expression of a modified foamy virus envelope protein
Douglas et al. Strategies to Adapt Adenoviral Vectors for Gene Therapy Applications

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)